Perspective Therapeutics, Inc. announced the first shipment and patient dosing from its second manufacturing facility for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals.
Located in Somerset, New Jersey, this facility is now operational to supply investigational products to support VMT-α-NET clinical studies, in addition to the Coralville, Iowa facility which has been producing the Company’s investigational products for over 15 months. With three manufacturing suites that can meet Current Good Manufacturing Practice (cGMP) requirements, the Somerset facility is expected to have the capacity to meet future clinical trial and commercial demands at major cancer treatment centers throughout the Northeastern U.S. Until the close of its acquisition by Perspective in March 2024, this facility was operated by Lantheus Holdings, Inc., the leading radiopharmaceutical-focused company. This facility previously produced Azedra, which contained a form of radioactive iodine and received approval from the U.S. Food & Drug Administration (FDA) in 2018 for the treatment of rare tumors of the adrenal gland.
"Today marks an exciting milestone as we start shipping investigational products from this state-of-the-art facility,” commented Shane Cobb, Perspective’s Executive Vice President of Operations. “Going operational seven months after taking possession of the facility allows us to accelerate our efforts in delivering investigational products and, pending approval, new radiopharmaceutical therapies."
"We are thrilled to celebrate the opening of this facility, which is a step forward in building out our manufacturing and supply chain capabilities,” said Thijs Spoor, Perspective’s Chief Executive Officer. “It reflects our commitment to delivering targeted alpha-particle therapies to patients in critical need. We believe our network approach aligns with patient interest and the half-life profiles of isotopes contained in our investigational products. We look forward to replicating this effort and adding sites strategically to enhance our network to support key treatment hubs across the U.S."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!